32.jpg)
56.jpg)
PROTEASOME INHIBITOR
Patent number:
EP24382811
No items found.
Researchers at the Universitat Jaume I and the Max Planck Institute have developed new proteasome inhibitors with pharmacological properties different from those developed until now.
Countries:
Spain
Regions:
Valencian Community
Centers:
UNIVERSITAT JAUME I
Other entities:
Max Planck Institute
Sectors:
Health
Subsectors:
TRL Level:
TRL 3 – experimental proof of concept
BRL Level:
PDF Link:
Download hereVideo Link:
Watch it hereSustainable Development Goal:
SDG03: Good health and well-being
Applications
- Compounds with higher affinity and more specific. - Improved properties with respect to commercial drugs (higher target selectivity and increased affinity).
Comments
The technology is the subject of a project to valorize research results.
Other related patents
Health
ORGANOID CULTURE SYSTEM AND METHOD FOR STERILISING AN ORGANOID CULTURE SYSTEM
Health
Controlled release system based on the interaction between organic vesicles and porous materials equipped with molecular gates
Health